17 completed, 6 not yet recruiting, 2 terminated, 2 unknown. 29 Phase 2, 6 Phase 1, 4 Phase 3.
Follow Malaria, Vivax: new trials by email Literature Review of Malaria, Vivax trials Research Report on Malaria, Vivax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-19 | 2026-11-16 |
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| Postpartum 8-aminoquinoline Breast Milk Study Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers | Phase 2 / Phase 3 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-03-18 |
| Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia PvCS/Montanide ISA-51 VG Vaccine, Placebo - Montanide ISA-51 VG Adjuvant Alone - Plasmodium Vivax Malaria, Plasmodium Vivax Infection | Phase 2 | Not yet recruiting | Malaria Vaccine and Drug Development Center | 72 | 2026-01-19 | 2026-01-28 |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer Plasmodium immunotherapy - Advanced Ovarian Cancer | Phase 2 / Phase 3 | Not yet recruiting | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | 30 | 2024-07-20 | 2024-07-22 |
| Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia Primaquine double dose over 14 days, Primaquine single dose over 14 days - Malaria, Vivax, Relapse | Phase 2 / Phase 3 | Withdrawn | University of California, San Francisco | 2023-01-20 | 2023-05-11 | |
| Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children Primaquine - Malaria, Vivax | Phase 2 | Completed | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 100 | 2021-08-26 | 2025-02-20 |
| Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers Vaccine PvCS N+C+R 150 mcg, Placebo SSN Montanide ISA-51 1 mL - Malaria, Vivax | Phase 2 | Unknown | Malaria Vaccine and Drug Development Center | 120 | 2021-06-01 | 2021-03-01 |
| Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria (+)-SJ000557733 (SJ733) - Malaria, Falciparum, Malaria, Vivax | Phase 2 | Completed | R. Kiplin Guy | 22 | 2021-04-14 | 2023-12-04 |
| Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 PvDBPII/Matrix-M1 - Malaria, Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 24 | 2020-01-24 | 2024-11-25 |
| VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines ChAd63 PvDBP and MVA PvDBP - Malaria, Vivax | Phase 2 | Completed | University of Oxford | 16 | 2019-07-18 | 2024-04-12 |
| Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua Dihydroartemisinin, Piperaquine, Primaquine - Malaria,Falciparum, Malaria, Vivax | Phase 2 | Completed | Syamsudin Abdillah,Ph.D, Pharm D | 50 | 2019-01-11 | 2023-09-13 |
| Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients Chloroquine, Primaquine - Vivax Malaria, G6PD Deficiency | Phase 2 | Completed | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 106 | 2018-07-20 | 2025-02-20 |
| A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria Tafenoquine, Chloroquine - Malaria, Vivax | Phase 2 | Completed | GlaxoSmithKline | 60 | 2017-02-06 | 2020-11-02 |
| Plasmodium Immunotherapy for Lung Cancer Blood-stage infection of P. vivax - Lung Cancer, Nonsmall Cell | Phase 1 / Phase 2 | Unknown | State Key Laboratory of Respiratory Disease | 30 | 2016-06-27 | 2023-06-22 |
| P.Vivax Treatment Trial Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ), Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo - Plasmodium Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2016-06-14 | 2022-03-02 |
| Methylene Blue Against Vivax Malaria in Ethiopia Artemeter-Lumefantrine and MB (combination therapy), Artemeter-Lumefantrine (combination therapy), Artemeter-Lumefantrine and Primaquine (combination therapy) - Vivax Malaria | Phase 2 | Withdrawn | Heidelberg University | 2016-04-01 | 2020-03-25 | |
| DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax DSM265 400mg, DSM265 xmg, DSM265 ymg - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Phase 2 | Completed | Medicines for Malaria Venture | 45 | 2016-01-01 | 2016-06-22 |
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection Chloroquine, Primaquine - Malaria, Vivax | Phase 2 / Phase 3 | Completed | Oswaldo Cruz Foundation | 204 | 2014-08-01 | 2016-02-25 |
Showing 20 of 29. Sign in to see all of them.
Malaria (11) · Malaria, Falciparum (4) · Glucosephosphate Dehydrogenase Deficiency (2) · Recurrence (2) · Anemia (1) · Breast Feeding (1) · Carcinoma, Non-Small-Cell Lung (1) · Chills (1) · Fever (1) · Infections (1) · Parasitemia (1)
Mosquito-Borne Diseases (29) · Parasitic Diseases (29) · Protozoan Infections (29) · Vector Borne Diseases (29) · Infections (28) · Malaria (18) · Pathological Conditions, Signs and Symptoms (4) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Pathologic Processes (3) · Anemia (2) · Anemia, Hemolytic (2) · Anemia, Hemolytic, Congenital (2) · Carbohydrate Metabolism, Inborn Errors (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)
Primaquine (10) · Chloroquine (9) · tafenoquine (6) · SJ733 (2) · artenimol (2) · piperaquine (2) · 3,7-bis(diethylamino)phenothiazin-5-ium (1) · Combined Modality Therapy (1) · DSM265 (1) · Food (1) · Matrix-M (1) · Tinidazole (1) · Water (1) · artefenomel (1) · bitter melon extract (1)
University of Oxford (4) · Malaria Vaccine and Drug Development Center (3) · Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (2) · GlaxoSmithKline (2) · Medicines for Malaria Venture (2) · R. Kiplin Guy (2) · U.S. Army Medical Research and Development Command (2) · Alfasigma S.p.A. (1) · CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. (1) · Curtin University (1) · Heidelberg University (1) · London School of Hygiene and Tropical Medicine (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oswaldo Cruz Foundation (1) · Socrates Herrera Valencia (1)
Colombia (5) · Brazil (4) · Peru (4) · Thailand (4) · China (2) · United Kingdom (2) · United States (2) · Vietnam (2) · Bangladesh (1) · Cambodia (1) · Ethiopia (1) · France (1) · Germany (1) · India (1) · Indonesia (1)
Alejandro L Cuentas, MD, PhD (1) · Alejandro L Cuentas,, MD, PhD (1) · Alejandro Llanos, Professor (1) · Angela M Minassian, Dr (1) · Angela M Minassian, MBBS MA DPhil MRCP FRCPath (1) · Brioni Moore, PhD (1) · Christoph Hatz, Prof Dr Med (1) · Cindy Chu, MD, PhD (1) · Francois Nosten, MD (1) · Guo Shuiqun, Ph.D., M.D. (1) · Jason Bennett, MD (1) · Marcus VG Lacerda, MD, PhD (1)
PMID 35664997, PMID 17707447, PMID 21292874, PMID 21931708, PMID 23718705, PMID 24088113, PMID 24360369, PMID 24963662, PMID 26248362, PMID 26448141, PMID 26500351, PMID 26654101, PMID 28318100, PMID 29121061, PMID 29909069, PMID 30269312, PMID 30650322, PMID 30782991, PMID 31888643, PMID 31900172, PMID 34161579, PMID 34871570, PMID 39785834, PMID 41430686
U01AI195203 (1)